<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Iakovis, P</style></author><author><style face="normal" font="default" size="100%">Anyfantakis,Z.A.</style></author><author><style face="normal" font="default" size="100%">LIMAS, C</style></author><author><style face="normal" font="default" size="100%">Kroupis, C.</style></author><author><style face="normal" font="default" size="100%">Degiannis, D.</style></author><author><style face="normal" font="default" size="100%">Cokkinos, D.V.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Increased inflammatory response in patients with dilated cardiomyopathy is associated with dyslipidemia: Effects of statin therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Angiology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cardiomyopathy,Dilated</style></keyword><keyword><style  face="normal" font="default" size="100%">Complications</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Dyslipidemias</style></keyword><keyword><style  face="normal" font="default" size="100%">Etiology</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Greece</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors</style></keyword><keyword><style  face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Simvastatin</style></keyword><keyword><style  face="normal" font="default" size="100%">therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">therapy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011/01//</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">PM:21134995</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">62</style></volume><pages><style face="normal" font="default" size="100%">55 - 61</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Dilated cardiomyopathy (DCM) is associated with increased inflammatory response reflected among other markers in high-sensitivity C-reactive protein (hsCRP) and soluble interleukin-2 receptor (sIL-2R) levels. We examined prospectively 60 consecutive patients with DCM. Of them, 30 were dyslipidemic (group I) and 30 normolipidemic (group II). Group I patients were randomized to either simvastatin therapy (20 mg/day, group Ia, n = 15) or hypolipidemic diet therapy (group Ib, n = 15). Patients were re-evaluated 6 months later. High-sensitivity C-reactive protein and sIL-2R levels were significantly higher in group I compared with group II patients (19.5 +/- 3.4 vs 3.03 +/- 3.5 mg/L, P = .01, 1137 +/- 441 vs 599 +/- 235 pg/mL, P = .001, respectively). There was a significant correlation between sIL-2R and hsCRP levels in dyslipidemic patients but not in normolipidemic patients. Significant reduction of hsCRP and sIL-2R levels was observed only in group Ia patients. Patients with DCM having dyslipidemia have increased inflammatory response, which is reduced after 6 months of statin therapy</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><notes><style face="normal" font="default" size="100%">DA - 20101207 IS - 1940-1574 (Electronic) IS - 0003-3197 (Linking) LA - eng PT - Journal Article PT - Randomized Controlled Trial RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - AGG2FN16EV (Simvastatin) SB - IM</style></notes></record></records></xml>